A Milestone in Advanced Bladder Cancer Treatment: FDA Approval of PADCEV with KEYTRUDA
Astellas and Pfizer proudly announce the groundbreaking approval by the U.S. Food and Drug Administration (FDA) of PADCEV® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), in combination with KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This approval marks a paradigm shift in the therapeutic landscape for advanced bladder cancer, providing a compelling alternative to platinum-containing chemotherapy, the current standard of care.
The approval is anchored in the Phase 3 EV-302 clinical trial, also known as KEYNOTE-A39, where the combination of PADCEV and pembrolizumab demonstrated a remarkable nearly doubled median overall survival (OS) and median progression-free survival (PFS) in comparison to platinum-containing chemotherapy. Notably, this combination is the first regimen demonstrating superiority over platinum chemotherapy, a historic standard of care.
Drug Details
PADCEV, a first-in-class ADC directed to Nectin-4, a protein highly expressed in bladder cancer, exerts its anticancer activity by internalizing and releasing the anti-tumor agent monomethyl auristatin E (MMAE) into cells, inducing cell cycle arrest and programmed cell death. The combination with pembrolizumab enhances the therapeutic efficacy of PADCEV.
The combination of PADCEV and pembrolizumab represents a synergistic approach, targeting multiple pathways in the cancer microenvironment. This dual mechanism holds promise in transforming the standard of care for advanced bladder cancer, as demonstrated by the significant improvements in OS and PFS observed in the EV-302 trial.
Recommended by LinkedIn
Trial Details
The EV-302 trial, an open-label, randomized, controlled Phase 3 study, enrolled 886 patients with previously untreated la/mUC. The combination of PADCEV and pembrolizumab, as compared to chemotherapy, met its dual primary endpoints of OS and PFS, showcasing a 53% reduction in the risk of death and a 55% reduction in the risk of cancer progression or death.
The safety profile of PADCEV plus pembrolizumab, consistent with previous findings, revealed common adverse events, including laboratory abnormalities. Notably, the safety results were in line with those reported in cisplatin-ineligible patients, and no new safety issues were identified.
The FDA approval of PADCEV in combination with pembrolizumab signifies a significant advancement in the treatment landscape for advanced bladder cancer. The results from the EV-302 trial, with its notable improvements in OS and PFS, underscore the potential for this combination to redefine the standard of care. As we move forward, ongoing investigational trials and a comprehensive understanding of the evolving therapeutic landscape will further shape the future of advanced urothelial cancer treatment.
#BladderCancer #PADCEV #EnfortumabVedotin #KEYTRUDA #Pembrolizumab #Nectin-4 #EV-302 #KEYNOTE-A39